South Korean biotech Eutilex has seen a $21 billion KRW ($18.9 million) Series A funding boost as it looks to take its lead cancer med into midstage testing.

The European Medicines Agency has accepted Regeneron and Sanofi’s dupilumab for review.

Researchers at Toronto’s Princess Margaret Cancer Centre have landed on a new biomarker that can predict if patients with acute myeloid leukemia will respond…

Abbott has been squirming for months over its Alere acquisition, even offering the diagnostics maker $50 million to exit the deal. Now, Abbott is putting its…

After looking into a local Medtronic unit for monopolistic activities, Chinese regulators are charging the company 118.5 million yuan ($17.2 million).

Nordic Nanovector has raised $60 million to test its CD37-targeting antibody-radionuclide conjugate in combination with rituximab.

AbbVie missed its survival targets in a new midstage trial of its PARP breast cancer candidate veliparib in combo with chemo, but the company is still hopeful…

Regulus has bulked up its pipeline with two new drug candidates due to start trials next year, as it tries to get lead hep C candidate back on track.